Crohn Disease Prognostic Panel
2001613
Ordering Recommendation
May aid in prognostication of confirmed Crohn disease (CD). May also be useful in the diagnosis of CD.
Mnemonic
CROHN PAN
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Tue
Reported
1-8 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Serum separator tube (SST).  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Plasma, other body fluids, grossly icteric, heat-inactivated, grossly hemolyzed, severely lipemic, or contaminated specimens.  
Remarks
  
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
(avoid repeated freeze/thaw cycles)  
Reference Interval
 
 
Available Separately Components Reference Interval
No Saccharomyces cerevisiae Antibody (gASCA), IgG 0-​44 Units: Negative
45-​50 Units: Equivocal
51 Units or greater: Positive
No Laminaribioside Carbohydrate Antibody (ALCA), IgG 0-​54 Units: Negative
55-​60 Units: Equivocal
61 Units or greater: Positive
No Mannobioside Carbohydrate Antibody (AMCA), IgG 0-​89 Units: Negative
90-​100 Units: Equivocal
101 Units or greater: Positive
No Chitobioside Carbohydrate Antibody (ACCA), IgA 0-​79 Units: Negative
80-​90 Units: Equivocal
91 Units or greater: Positive
   
Interpretive Data
If only one of the four markers in the Crohn Disease Prognostic Panel is positive, clinical specificity is at least 85 percent. If all four markers are negative and inflammatory bowel disease (IBD) is suspected, testing for ANCA by IFA is recommended to confirm or exclude the possibility of ulcerative colitis (UC).

See Compliance Statement A: www.aruplab.com/CS
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
 
Note
 
CPT Code(s)
86671; 83516 x3
Components
Component Test Code*Component Chart NameLOINC
2001609Saccharomyces cerevisiae Ab (gASCA), IgG47321-5
2001610Mannobioside Carbohydrate Ab (AMCA), IgG53597-1
2001611Laminaribioside Carbohydrate Ab ALCA IgG53596-3
2001612Chitobioside Carbohydrate Ab (ACCA), IgA53594-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chitobioside Carbohydrate Antibody (ACCA), IgA
  • Glycan Antibodies
  • IBD Prognostic Panel
  • IBDX
  • Inflammatory Bowel Disease Prognostic Panel
  • Laminaribioside Carbohydrate Antibody (ALCA), IgG
  • Saccharomyces cerevisiae Antibody (gASCA), IgG